Cargando…

Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports

BACKGROUND: From May 2020 to January 2021, we enrolled 1233 health care workers (HCW) from Danish Hospitals in a randomized trial evaluating whether Bacille Calmette-Guérin (BCG) provides protection against COVID-19. Participants were randomized 1:1 to BCG vs saline and followed for 6 months. From D...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Libin, Madsen, Anne Marie Rosendahl, Schaltz-Buchholzer, Frederik, Ostenfeld, Anne, Netea, Mihai G., Benn, Christine Stabell, Kofoed, Poul-Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685493/
https://www.ncbi.nlm.nih.gov/pubmed/34930152
http://dx.doi.org/10.1186/s12879-021-06949-0
_version_ 1784617843468271616
author Mohamed, Libin
Madsen, Anne Marie Rosendahl
Schaltz-Buchholzer, Frederik
Ostenfeld, Anne
Netea, Mihai G.
Benn, Christine Stabell
Kofoed, Poul-Erik
author_facet Mohamed, Libin
Madsen, Anne Marie Rosendahl
Schaltz-Buchholzer, Frederik
Ostenfeld, Anne
Netea, Mihai G.
Benn, Christine Stabell
Kofoed, Poul-Erik
author_sort Mohamed, Libin
collection PubMed
description BACKGROUND: From May 2020 to January 2021, we enrolled 1233 health care workers (HCW) from Danish Hospitals in a randomized trial evaluating whether Bacille Calmette-Guérin (BCG) provides protection against COVID-19. Participants were randomized 1:1 to BCG vs saline and followed for 6 months. From December 2020, Covid-19 vaccines were offered to the HCW. In most cases, BCG vaccination results in a characteristic scar. Reactivation of the BCG scar has been described in children during viral infections and following influenza vaccination, but is mostly associated to Kawasaki’s disease, a disease entity with pathogenesis likely similar to the child Covid-19 complication MIS-C: Multi-System Inflammatory Syndrome. Reactivation of scars after neonatal BCG vaccination has recently been described in four women after Covid-19 mRNA vaccination. Two of our trial participants experienced reactivation of their novel BCG scars after receiving mRNA Covid-19 vaccination 6 to 8 months post-BCG. CASE PRESENTATIONS: Two female HCW participants that had been randomly allocated to BCG in the BCG-DENMARK-COVID trial, spontaneously reported itching and secretion at the BCG scar site after having received mRNA Covid-19 vaccination (Moderna and Pfizer-BioNTech) 6 to 8 months following inclusion and BCG vaccination. One participant, who had a larger BCG skin reaction, noticed re-appearing symptoms after both the first and the second COVID-vaccine dose, while the other participant only noted symptoms after the second dose. Both had been BCG vaccinated during childhood, and no reactivation was noted in the older scars. No treatment was needed or provided. CONCLUSIONS: The reactivation of the BCG scar after receiving mRNA vaccine might have been caused by cross-reactivity between BCG and SARS-CoV-2. In both cases, the symptoms were bothersome, but self-limiting and left no sequelae. The risk of reactivation at the scar site is thus not a reason to avoid vaccination with either vaccine.
format Online
Article
Text
id pubmed-8685493
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86854932021-12-20 Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports Mohamed, Libin Madsen, Anne Marie Rosendahl Schaltz-Buchholzer, Frederik Ostenfeld, Anne Netea, Mihai G. Benn, Christine Stabell Kofoed, Poul-Erik BMC Infect Dis Case Report BACKGROUND: From May 2020 to January 2021, we enrolled 1233 health care workers (HCW) from Danish Hospitals in a randomized trial evaluating whether Bacille Calmette-Guérin (BCG) provides protection against COVID-19. Participants were randomized 1:1 to BCG vs saline and followed for 6 months. From December 2020, Covid-19 vaccines were offered to the HCW. In most cases, BCG vaccination results in a characteristic scar. Reactivation of the BCG scar has been described in children during viral infections and following influenza vaccination, but is mostly associated to Kawasaki’s disease, a disease entity with pathogenesis likely similar to the child Covid-19 complication MIS-C: Multi-System Inflammatory Syndrome. Reactivation of scars after neonatal BCG vaccination has recently been described in four women after Covid-19 mRNA vaccination. Two of our trial participants experienced reactivation of their novel BCG scars after receiving mRNA Covid-19 vaccination 6 to 8 months post-BCG. CASE PRESENTATIONS: Two female HCW participants that had been randomly allocated to BCG in the BCG-DENMARK-COVID trial, spontaneously reported itching and secretion at the BCG scar site after having received mRNA Covid-19 vaccination (Moderna and Pfizer-BioNTech) 6 to 8 months following inclusion and BCG vaccination. One participant, who had a larger BCG skin reaction, noticed re-appearing symptoms after both the first and the second COVID-vaccine dose, while the other participant only noted symptoms after the second dose. Both had been BCG vaccinated during childhood, and no reactivation was noted in the older scars. No treatment was needed or provided. CONCLUSIONS: The reactivation of the BCG scar after receiving mRNA vaccine might have been caused by cross-reactivity between BCG and SARS-CoV-2. In both cases, the symptoms were bothersome, but self-limiting and left no sequelae. The risk of reactivation at the scar site is thus not a reason to avoid vaccination with either vaccine. BioMed Central 2021-12-20 /pmc/articles/PMC8685493/ /pubmed/34930152 http://dx.doi.org/10.1186/s12879-021-06949-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Mohamed, Libin
Madsen, Anne Marie Rosendahl
Schaltz-Buchholzer, Frederik
Ostenfeld, Anne
Netea, Mihai G.
Benn, Christine Stabell
Kofoed, Poul-Erik
Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports
title Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports
title_full Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports
title_fullStr Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports
title_full_unstemmed Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports
title_short Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports
title_sort reactivation of bcg vaccination scars after vaccination with mrna-covid-vaccines: two case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685493/
https://www.ncbi.nlm.nih.gov/pubmed/34930152
http://dx.doi.org/10.1186/s12879-021-06949-0
work_keys_str_mv AT mohamedlibin reactivationofbcgvaccinationscarsaftervaccinationwithmrnacovidvaccinestwocasereports
AT madsenannemarierosendahl reactivationofbcgvaccinationscarsaftervaccinationwithmrnacovidvaccinestwocasereports
AT schaltzbuchholzerfrederik reactivationofbcgvaccinationscarsaftervaccinationwithmrnacovidvaccinestwocasereports
AT ostenfeldanne reactivationofbcgvaccinationscarsaftervaccinationwithmrnacovidvaccinestwocasereports
AT neteamihaig reactivationofbcgvaccinationscarsaftervaccinationwithmrnacovidvaccinestwocasereports
AT bennchristinestabell reactivationofbcgvaccinationscarsaftervaccinationwithmrnacovidvaccinestwocasereports
AT kofoedpoulerik reactivationofbcgvaccinationscarsaftervaccinationwithmrnacovidvaccinestwocasereports